<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font18 { font-size : 18; } .font24 { font-size : 24; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">and </span>
   <span class="font24">the </span>
   <span class="font18">with </span>
   <span class="font16">â€". </span>
   <span class="font16">for </span>
   <span class="font15">virus </span>
   <span class="font14">âœ" </span>
   <span class="font14">viral </span>
   <span class="font13">antiviral </span>
   <span class="font13">HIV </span>
   <span class="font13">treatment </span>
   <span class="font12">patients </span>
   <span class="font12">(nâ€‰=â€‰): </span>
   <span class="font12">vitro </span>
   <span class="font12">{background </span>
   <span class="font12">al. </span>
   <span class="font12">replication </span>
   <span class="font12">RCT </span>
   <span class="font11">The </span>
   <span class="font11">respiratory </span>
   <span class="font11">was </span>
   <span class="font11">infection </span>
   <span class="font11">â€¢ </span>
   <span class="font11">virus; </span>
   <span class="font11">are </span>
   <span class="font11">clinical </span>
   <span class="font11">margin </span>
   <span class="font11">protein </span>
   <span class="font11">DMARDs </span>
   <span class="font11">virus, </span>
   <span class="font11">{border-style </span>
   <span class="font11">activity </span>
   <span class="font11">human </span>
   <span class="font11">hydroxyurea </span>
   <span class="font11">immune </span>
   <span class="font11">immunodeficiency </span>
   <span class="font11">px;} </span>
   <span class="font11">syndrome </span>
   <span class="font11">were </span>
   <span class="font11">#ffffff;} </span>
   <span class="font11">hepatitis </span>
   <span class="font11">inhibits </span>
   <span class="font11">HCV </span>
   <span class="font11">acute </span>
   <span class="font11">from </span>
   <span class="font11">has </span>
   <span class="font11">minocycline </span>
   <span class="font11">severe </span>
   <span class="font11">showed </span>
   <span class="font11">RNA </span>
   <span class="font11">coronavirus </span>
   <span class="font11">effect </span>
   <span class="font11">efficacy </span>
   <span class="font11">which </span>
   <span class="font11">been </span>
   <span class="font11">disease </span>
   <span class="font11">including </span>
   <span class="font11">leflunomide </span>
   <span class="font11">study </span>
   <span class="font11">through </span>
   <span class="font10">COVID- </span>
   <span class="font10">CsA </span>
   <span class="font10">MMF </span>
   <span class="font10">control </span>
   <span class="font10">drugs </span>
   <span class="font10">influenza </span>
   <span class="font10">may </span>
   <span class="font10">studies </span>
   <span class="font10">that </span>
   <span class="font10">therapy </span>
   <span class="font10">Leflunomide </span>
   <span class="font10">activation </span>
   <span class="font10">controlled </span>
   <span class="font10">randomized </span>
   <span class="font10">significant </span>
   <span class="font10">such </span>
   <span class="font10">Dis; </span>
   <span class="font10">IL-, </span>
   <span class="font10">Infect </span>
   <span class="font10">SARS-CoV- </span>
   <span class="font10">T-cell </span>
   <span class="font10">acid </span>
   <span class="font10">baricitinib </span>
   <span class="font10">chronic </span>
   <span class="font10">dengue </span>
   <span class="font10">have </span>
   <span class="font10">hydroxychloroquine </span>
   <span class="font10">immunosuppressive </span>
   <span class="font10">infections. </span>
   <span class="font10">inhibition </span>
   <span class="font10">other </span>
   <span class="font10">potential </span>
   <span class="font10">production </span>
   <span class="font10">revealed </span>
   <span class="font10">review </span>
   <span class="font10">trial </span>
   <span class="font10">type </span>
   <span class="font10">However, </span>
   <span class="font10">active </span>
   <span class="font10">also </span>
   <span class="font10">but </span>
   <span class="font10">cells </span>
   <span class="font10">chloroquine </span>
   <span class="font10">herpes </span>
   <span class="font10">infection. </span>
   <span class="font10">mortality </span>
   <span class="font10">rate </span>
   <span class="font10">reduced </span>
   <span class="font10">results </span>
   <span class="font10">simplex </span>
   <span class="font10">thalidomide </span>
   <span class="font10">trials </span>
   <span class="font10">use </span>
   <span class="font10">DOI: </span>
   <span class="font10">Epub </span>
   <span class="font10">HCQ </span>
   <span class="font10">Inhibit </span>
   <span class="font10">JAK </span>
   <span class="font10">SARS-CoV-, </span>
   <span class="font10">against </span>
   <span class="font10">ahead </span>
   <span class="font10">cell </span>
   <span class="font10">demonstrated </span>
   <span class="font10">disease-modifying </span>
   <span class="font10">effects </span>
   <span class="font10">immunosuppressants </span>
   <span class="font10">improved </span>
   <span class="font10">into </span>
   <span class="font10">lupus </span>
   <span class="font10">not </span>
   <span class="font10">print </span>
   <span class="font10">trial. </span>
   <span class="font10">used </span>
   <span class="font10">Human </span>
   <span class="font10">Japanese </span>
   <span class="font10">Res </span>
   <span class="font10">This </span>
   <span class="font10">after </span>
   <span class="font10">al.A </span>
   <span class="font10">all </span>
   <span class="font10">antiretroviral </span>
   <span class="font10">associated </span>
   <span class="font10">benefit </span>
   <span class="font10">cells. </span>
   <span class="font10">cellular </span>
   <span class="font10">cytokine </span>
   <span class="font10">diseases </span>
   <span class="font10">effective </span>
   <span class="font10">encephalitis </span>
   <span class="font10">especially </span>
   <span class="font10">high </span>
   <span class="font10">higher </span>
   <span class="font10">host </span>
   <span class="font10">kinase </span>
   <span class="font10">mitochondrial </span>
   <span class="font10">one </span>
   <span class="font10">pilot </span>
   <span class="font10">px; </span>
   <span class="font10">renal </span>
   <span class="font10">some </span>
   <span class="font10">than </span>
   <span class="font10">there </span>
   <span class="font10">this </span>
   <span class="font10">two </span>
   <span class="font10">{font-family </span>
   <span class="font10">â–³ </span>
   <span class="font10">Clin </span>
   <span class="font10">HBV </span>
   <span class="font10">HIV, </span>
   <span class="font10">Nile </span>
   <span class="font10">RSV </span>
   <span class="font10">West </span>
   <span class="font10">Zika </span>
   <span class="font10">acid; </span>
   <span class="font10">activities </span>
   <span class="font10">combination </span>
   <span class="font10">compared </span>
   <span class="font10">could </span>
   <span class="font10">cyclophilin </span>
   <span class="font10">decrease </span>
   <span class="font10">decreased </span>
   <span class="font10">font-size </span>
   <span class="font10">function </span>
   <span class="font10">further </span>
   <span class="font10">hydroxyurea. </span>
   <span class="font10">its </span>
   <span class="font10">loads </span>
   <span class="font10">mechanisms </span>
   <span class="font10">mycophenolate </span>
   <span class="font10">plus </span>
   <span class="font10">report </span>
   <span class="font10">response </span>
   <span class="font10">safety </span>
   <span class="font10">syncytial </span>
   <span class="font10">treated </span>
   <span class="font10">viruses </span>
   <span class="font10">Antimicrob </span>
   <span class="font10">Case </span>
   <span class="font10">Cyclosporine </span>
   <span class="font10">DNA </span>
   <span class="font10">HCV, </span>
   <span class="font10">Influenza </span>
   <span class="font10">Minocycline </span>
   <span class="font10">RCT, </span>
   <span class="font10">Thalidomide </span>
   <span class="font10">Tsai </span>
   <span class="font10">Virol; </span>
   <span class="font10">animal </span>
   <span class="font10">both </span>
   <span class="font10">case </span>
   <span class="font10">concomitant </span>
   <span class="font10">diseases. </span>
   <span class="font10">double; </span>
   <span class="font10">essential </span>
   <span class="font10">expression </span>
   <span class="font10">highly </span>
   <span class="font10">infections </span>
   <span class="font10">moderate </span>
   <span class="font10">mofetil </span>
   <span class="font10">mycophenolic </span>
   <span class="font10">positive </span>
   <span class="font10">receptors </span>
   <span class="font10">reduction </span>
   <span class="font10">rheumatoid </span>
   <span class="font10">role </span>
   <span class="font10">study. </span>
   <span class="font10">under </span>
   <span class="font10">â€‰mg </span>
   <span class="font10">Although </span>
   <span class="font10">Baricitinib </span>
   <span class="font10">Biochem </span>
   <span class="font10">CMV, </span>
   <span class="font10">COVID-: </span>
   <span class="font10">DMARDs, </span>
   <span class="font10">Dengue </span>
   <span class="font10">East </span>
   <span class="font10">HBV, </span>
   <span class="font10">HSV </span>
   <span class="font10">HSV, </span>
   <span class="font10">Hydroxyurea </span>
   <span class="font10">Middle </span>
   <span class="font10">Proposed </span>
   <span class="font10">Reduce </span>
   <span class="font10">Res; </span>
   <span class="font10">Ther; </span>
   <span class="font10">Tofacitinib </span>
   <span class="font10">agents </span>
   <span class="font10">al., </span>
   <span class="font10">al.Hydroxychloroquine </span>
   <span class="font10">al.Minocycline </span>
   <span class="font10">antirheumatic </span>
   <span class="font10">blocking </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">choice </span>
   <span class="font10">cognitive </span>
   <span class="font10">cyclophilins </span>
   <span class="font10">cyclosporine </span>
   <span class="font10">cytokines </span>
   <span class="font10">drug </span>
   <span class="font10">even </span>
   <span class="font10">greater </span>
   <span class="font10">group </span>
   <span class="font10">had </span>
   <span class="font10">improvement </span>
   <span class="font10">inhibitors </span>
   <span class="font10">less </span>
   <span class="font10">novel </span>
   <span class="font10">part </span>
   <span class="font10">permeability </span>
   <span class="font10">phase </span>
   <span class="font10">placebo </span>
   <span class="font10">prevents </span>
   <span class="font10">property </span>
   <span class="font10">pyrimidine </span>
   <span class="font10">significantly </span>
   <span class="font10">solid; </span>
   <span class="font10">specific </span>
   <span class="font10">still </span>
   <span class="font10">suggested </span>
   <span class="font10">systemic </span>
   <span class="font10">target </span>
   <span class="font10">three </span>
   <span class="font10">tofacitinib </span>
   <span class="font10">transition </span>
   <span class="font10">transplant </span>
   <span class="font10">trial; </span>
   <span class="font10">viremia </span>
   <span class="font10">while </span>
   <span class="font10">without </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">AIDS; </span>
   <span class="font10">Animal </span>
   <span class="font10">BKV, </span>
   <span class="font10">Betaretrovirus </span>
   <span class="font10">CMV </span>
   <span class="font10">COVID-. </span>
   <span class="font10">Cell </span>
   <span class="font10">Chemother; </span>
   <span class="font10">Clinical </span>
   <span class="font10">Flavivirus </span>
   <span class="font10">G-associated </span>
   <span class="font10">HCQ, </span>
   <span class="font10">HHV- </span>
   <span class="font10">HIV-infected </span>
   <span class="font10">IFNs </span>
   <span class="font10">IMPDH </span>
   <span class="font10">Int </span>
   <span class="font10">Kaposiâ€™s </span>
   <span class="font10">MERS-CoV </span>
   <span class="font10">Med </span>
   <span class="font10">Mol </span>
   <span class="font10">Mycophenolate </span>
   <span class="font10">SARS </span>
   <span class="font10">Table </span>
   <span class="font10">Therefore, </span>
   <span class="font10">Viral </span>
   <span class="font10">anti-inflammatory </span>
   <span class="font10">anti-rheumatic </span>
   <span class="font10">apoptosis </span>
   <span class="font10">atopic </span>
   <span class="font10">avian </span>
   <span class="font10">azithromycin </span>
   <span class="font10">because </span>
   <span class="font10">benefits </span>
   <span class="font10">better </span>
   <span class="font10">between </span>
   <span class="font10">binds </span>
   <span class="font10">bold </span>
   <span class="font10">can </span>
   <span class="font10">cells, </span>
   <span class="font10">chikungunya </span>
   <span class="font10">combined </span>
   <span class="font10">common </span>
   <span class="font10">complex </span>
   <span class="font10">conditions </span>
   <span class="font10">conducted </span>
   <span class="font10">counts </span>
   <span class="font10">courier; </span>
   <span class="font10">cyclin </span>
   <span class="font10">day </span>
   <span class="font10">dehydrogenase; </span>
   <span class="font10">disease, </span>
   <span class="font10">dividing </span>
   <span class="font10">double-blind, </span>
   <span class="font10">during </span>
   <span class="font10">em; </span>
   <span class="font10">endosomal </span>
   <span class="font10">enzyme </span>
   <span class="font10">evidence </span>
   <span class="font10">factor </span>
   <span class="font10">fever </span>
   <span class="font10">first </span>
   <span class="font10">glycosylation </span>
   <span class="font10">herpesvirus </span>
   <span class="font10">hospital </span>
   <span class="font10">hydroxychloroquine; </span>
   <span class="font10">immunosuppressants. </span>
   <span class="font10">infection: </span>
   <span class="font10">infections, </span>
   <span class="font10">inhibit </span>
   <span class="font10">inhibiting </span>
   <span class="font10">inhibitor </span>
   <span class="font10">inosine </span>
   <span class="font10">investigated </span>
   <span class="font10">kinase; </span>
   <span class="font10">leflunomide, </span>
   <span class="font10">leflunomide. </span>
   <span class="font10">liver </span>
   <span class="font10">lung </span>
   <span class="font10">major </span>
   <span class="font10">male </span>
   <span class="font10">mild </span>
   <span class="font10">molluscum </span>
   <span class="font10">monophosphate </span>
   <span class="font10">more </span>
   <span class="font10">most </span>
   <span class="font10">necrosis </span>
   <span class="font10">noted </span>
   <span class="font10">nâ€‰=â€‰: </span>
   <span class="font10">only </span>
   <span class="font10">organ </span>
   <span class="font10">outcomes </span>
   <span class="font10">patient </span>
   <span class="font10">per </span>
   <span class="font10">placebo-controlled </span>
   <span class="font10">pneumonia. </span>
   <span class="font10">primary </span>
   <span class="font10">pt;} </span>
   <span class="font10">randomized-controlled </span>
   <span class="font10">receptor </span>
   <span class="font10">recipients. </span>
   <span class="font10">reduces </span>
   <span class="font10">retrospective </span>
   <span class="font10">ribonucleic </span>
   <span class="font10">several </span>
   <span class="font10">studies. </span>
   <span class="font10">susceptibility </span>
   <span class="font10">symptoms </span>
   <span class="font10">synthesis </span>
   <span class="font10">synthesis, </span>
   <span class="font10">those </span>
   <span class="font10">tumor </span>
   <span class="font10">when </span>
  </p>
 </body>
</html>
